Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dong A University College Medicine, Pusan
Trichostatin A offers novel therapeutic strategy for osteosarcoma
November 6th, 2004
Trichostatin A offers a novel therapeutic strategy for treating osteosarcoma. "Although histone deacetylase (HDAC) inhibitors are emerging as a promising new treatment strategy in malignancy, how they exert their effect on osteosarcoama cells is as yet unclear. This study was undertaken to investigate the underlying mechanism of a HDAC inhibitor Trichostatin A (TSA)-induced apoptosis in a osteosarcoma cell line HOS," scientists in South Korea report. "We observed that TSA treatment decreased the viability of the cells and prominently increased acetylation of histone H3. Evidence was obtained indicating that TSA induced apoptosis of HOS cells as...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
